Molecular Profiling and Real-world Outcomes of BRAF V600E–Mutated Papillary Thyroid Cancer

甲状腺乳突癌 医学 癌症研究 甲状腺癌 内科学 仿形(计算机编程) 甲状腺 肿瘤科 病理 基因表达谱 癌症 乳头状癌 乳头状肿瘤 甲状腺癌
作者
Martina Chirra,Andrew Elliott,Hira Ghazal Shaikh,Julie McGrath,Dalia El-Gamal,Anthony Nicholas Karnezis,Farah Rukhsana Abdulla,Chukwuemeka V. Ikpeazu,Jennifer L. Leddon,Ammar W. Sukari,Dan P. Zandberg,Jennifer Maria Johnson,Lova Sun,Trisha Michel Wise-Draper
出处
期刊:Clinical Cancer Research [American Association for Cancer Research]
卷期号:32 (6): 1110-1119 被引量:5
标识
DOI:10.1158/1078-0432.ccr-25-3932
摘要

PURPOSE: Radioactive iodine-refractory papillary thyroid cancers (PTC) containing BRAF V600E mutations can be treated with BRAF/MEK inhibitors (BRAF/MEKi), but their effectiveness compared with tyrosine kinase inhibitors (TKI) and immunotherapy (IO) remains unclear. Therefore, we compared real-world survival and molecular/transcriptional signatures in patients with BRAF V600E-mutated (BRAF-mut) and BRAF wild-type (WT) PTC. EXPERIMENTAL DESIGN: Thyroid tumor samples underwent DNA/RNA next-generation sequencing and immunohistochemistry at Caris Life Sciences. Tumor microenvironment (TME) cell fractions were estimated by RNA deconvolution using quanTIseq. Insurance claims data were used to infer real-world overall survival (OS) and time on treatment. RESULTS: A total of 1,348 patients with differentiated thyroid cancer were identified; 81.8% were classified as PTC, of which 68.4% harbored a BRAF V600E mutation. TERT promoter mutations were the most common mutation in PTC (72%) and were more prevalent in BRAF-mut versus BRAF-WT. Mutations in NRAS, HRAS, and KRAS, as well as RET, BRAF, and ETV6 gene fusions, were predominantly found in BRAF-WT PTC. BRAF-mut PTC were more often PD-L1+ (33% vs. 18%, P < 0.001) and had significantly higher IFNγ scores. OS was not significantly different between patients with BRAF-mut versus BRAF-WT PTC. Systemic treatment (BRAF/MEKi, TKI, or IO) was not associated with significant differences in OS in BRAF-mut PTC, although there was a trend for longer OS in those treated with TKI compared with BRAF/MEKi or IO. CONCLUSIONS: BRAF-mut PTC is associated with a proinflammatory TME milieu compared with BRAF-WT PTC. However, in this limited dataset, treatment choice was not associated with differences in OS in BRAF-mut PTC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
喜喜发布了新的文献求助80
刚刚
研友_VZG7GZ的应助被hxd采纳,获得10
1秒前
1秒前
赘婿的应助被琪琪采纳,获得10
1秒前
暴躁的夏柳完成签到,获得积分10
1秒前
一哈哈完成签到,获得积分10
2秒前
2秒前
2秒前
chengcheng发布了新的文献求助20
3秒前
溯源完成签到,获得积分10
3秒前
潘果果完成签到,获得积分10
3秒前
奔跑的应助被khid采纳,获得10
4秒前
4秒前
奔跑的猫猫发布了新的文献求助200
4秒前
张卓情完成签到,获得积分20
4秒前
5秒前
华仔的应助被3277125325采纳,获得10
5秒前
6秒前
6秒前
xhzdd完成签到,获得积分10
6秒前
7秒前
7秒前
earthai完成签到,获得积分10
8秒前
元昭诩完成签到,获得积分10
8秒前
yoyo完成签到,获得积分10
8秒前
木木夕彤发布了新的文献求助10
8秒前
无极微光的应助被InaMikan采纳,获得20
9秒前
9秒前
斯文的炳完成签到,获得积分10
9秒前
羽晴完成签到 ,获得积分10
9秒前
chengcheng完成签到,获得积分10
10秒前
憨包发布了新的文献求助200
10秒前
小二郎的应助被零十一采纳,获得10
10秒前
Www发布了新的文献求助10
10秒前
优美的傲玉完成签到 ,获得积分10
11秒前
Z20251040501完成签到,获得积分20
11秒前
太叔白风完成签到,获得积分0
11秒前
张祖伦完成签到 ,获得积分10
11秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8187918
求助须知:如何正确求助?哪些是违规求助? 9575850
关于积分的说明 21843829
捐赠科研通 7785760
什么是DOI,文献DOI怎么找? 3435128
关于科研通互助平台的介绍 2559501
邀请新用户注册赠送积分活动 2482027